389 related articles for article (PubMed ID: 30700274)
1. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
Egli-Gany D; Spaar Zographos A; Diebold J; Masserey Spicher V; Frey Tirri B; Heusser R; Dillner J; Petignat P; Sahli R; Low N;
BMC Cancer; 2019 Jan; 19(1):111. PubMed ID: 30700274
[TBL] [Abstract][Full Text] [Related]
2. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
Perez S; Iñarrea A; Pérez-Tanoira R; Gil M; López-Díez E; Valenzuela O; Porto M; Alberte-Lista L; Peteiro-Cancelo MA; Treinta A; Carballo R; Reboredo MC; Alvarez-Argüelles ME; Purriños MJ
Virol J; 2017 Nov; 14(1):214. PubMed ID: 29110680
[TBL] [Abstract][Full Text] [Related]
3. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
4. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
7. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
[TBL] [Abstract][Full Text] [Related]
8. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.
Mesher D; Cuschieri K; Hibbitts S; Jamison J; Sargent A; Pollock KG; Powell N; Wilson R; McCall F; Fiander A; Soldan K
J Clin Pathol; 2015 Feb; 68(2):135-40. PubMed ID: 25410654
[TBL] [Abstract][Full Text] [Related]
9. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
Shing JZ; Hu S; Herrero R; Hildesheim A; Porras C; Sampson JN; Schussler J; Schiller JT; Lowy DR; Sierra MS; Carvajal L; Kreimer AR;
Lancet Oncol; 2022 Jul; 23(7):940-949. PubMed ID: 35709811
[TBL] [Abstract][Full Text] [Related]
10. Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact.
Pérez-Castro S; Lorenzo-Mahía Y; Iñarrea Fernández A; Lamas-González MJ; Sarán-Díez MT; Rubio-Alarcón J; Reboredo-Reboredo MC; Mosteiro-Lobato S; López-Miragaya I; Torres-Piñón J; Melón-García S
Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):479-85. PubMed ID: 24274937
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3.
Castle PE; Schiffman M; Wheeler CM; Wentzensen N; Gravitt PE
Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1675-81. PubMed ID: 20615885
[TBL] [Abstract][Full Text] [Related]
12. Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types.
Sand FL; Munk C; Frederiksen K; Junge J; Iftner T; Dehlendorff C; Kjaer SK
Int J Cancer; 2019 Apr; 144(8):1975-1982. PubMed ID: 30246864
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus type distribution in cervical intraepithelial neoplasia grade 2/3 and cervical cancer in Portugal: a CLEOPATRE II Study.
Pista A; de Oliveira CF; Lopes C; Cunha MJ;
Int J Gynecol Cancer; 2013 Mar; 23(3):500-6. PubMed ID: 23392401
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus in invasive cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela: a cross-sectional study.
Sánchez-Lander J; Cortiñas P; Loureiro CL; Pujol FH; Medina F; Capote-Negrín L; Bianchi G; García-Barriola V; Ruiz-Benni A; Avilán-Rovira J; Acosta H
Cancer Epidemiol; 2012 Oct; 36(5):e284-7. PubMed ID: 22608058
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and correlates of human papillomavirus genotypes among patients with cervical cancer and cervical intraepithelial neoplasia 3 in Israel.
Bassal R; Rosin LS; Schvimer M; Schejter E; Ozeryansky B; Kulik S; Bachar R; Shapira H; Sandbank J; Cohen D; Keinan-Boker L
J Low Genit Tract Dis; 2015 Apr; 19(2):161-4. PubMed ID: 25105719
[TBL] [Abstract][Full Text] [Related]
16. Distribution of HPV Genotype in Invasive Cervical Carcinoma and Cervical Intraepithelial Neoplasia in Zhejiang Province, Southeast China: Establishing the Baseline for Surveillance.
Xu XX; Zhou JS; Yuan SH; Yu H; Lou HM
Int J Environ Res Public Health; 2015 Sep; 12(9):10794-805. PubMed ID: 26404339
[TBL] [Abstract][Full Text] [Related]
17. Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer.
Inturrisi F; Lissenberg-Witte BI; Veldhuijzen NJ; Bogaards JA; Ronco G; Meijer CJLM; Berkhof J
Int J Cancer; 2021 Jan; 148(2):320-328. PubMed ID: 32663316
[TBL] [Abstract][Full Text] [Related]
18. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology.
Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews J
Gynecol Oncol; 2019 Apr; 153(1):26-33. PubMed ID: 30638767
[TBL] [Abstract][Full Text] [Related]
19. Incidence risk of cervical intraepithelial neoplasia 3 or more severe lesions is a function of human papillomavirus genotypes and severity of cytological and histological abnormalities in adult Japanese women.
Hosaka M; Fujita H; Hanley SJ; Sasaki T; Shirakawa Y; Abiko M; Kudo M; Kaneuchi M; Watari H; Kikuchi K; Sakuragi N
Int J Cancer; 2013 Jan; 132(2):327-34. PubMed ID: 22729477
[TBL] [Abstract][Full Text] [Related]
20. Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study.
Falcaro M; Soldan K; Ndlela B; Sasieni P
BMJ; 2024 May; 385():e077341. PubMed ID: 38749552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
